The Managing Director of  Cadila Healthcare Ltd, the pharmaceutical company whose injection Verafin got approval for threaupatic treatment of COVID-19, has said that the jab will be available at an affordable price. 

Also read: When is the production of Zydus Cadila’s Virafin likely to start?

Dr Sharvil Patel said that “the injection will definitely be affordable’ and will be decided keeping “access in mind”. He was speaking to news channel ETnow. The subcutaneous single-dose injection showed 91.5% positive result on mild to moderate COVID patients, he added.

Also read | Zydus Cadila%u2019s Virafin: Know all about the drug that got DGCI’s approval

On being asked when the injection will be available in market, Dr Patel said ‘very soon’, in a ‘few days’. He told the channel that around 50,000 doses will be in the market in a few days and the production will be increased 4 to 5 times in 45 days.

Also read | In vaccine mix-up, Maharashtra man given two doses of different COVID jabs

Also read |  Bharat Biotech’s Covaxin effective against strains found in UK, India: Study

Also read | What if you get doses of 2 different COVID vaccines? A study finds out

Also Read | Centre recommends 12-16 weeks gap between two doses of Covishield: Report

#Coronavirus #Health #Medicine #Virafin #covid19 #CoronavirusVaccine #MinistryOfHealthAndFamilyWelfare #India